태반 줄기 세포 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Placental Stem Cell Therapy Market is presumed to reach the market size of nearly USD 11.38 Billion by 2032 from USD 2.11 Billion in 2023 with a CAGR of 20.62% under the study period 2024-2032.

Placental stem cell therapy involves using stem cells derived from the placenta to treat various medical conditions. The placenta, a rich source of multipotent stem cells, can be harvested non-invasively after childbirth. These cells have the potential to develop into different types of cells and possess immunomodulatory properties, making them suitable for regenerative medicine and immune-related therapies. Applications include treating conditions such as blood disorders, neurological diseases, and tissue injuries. It offers advantages like reduced ethical concerns compared to embryonic stem cells and a lower risk of immune rejection due to the placenta's unique immunological profile.

MARKET DYNAMICS

The placental stem cell therapy market is propelled by the increasing prevalence of chronic and degenerative diseases, creating a significant demand for advanced and effective treatment options. Placental stem cells offer promising therapeutic potential due to their capacity to differentiate into various cell types and their immunomodulatory properties. Additionally, advancements in stem cell research & regenerative medicine enhance the understanding and application of placental stem cells, driving market growth. Compared to embryonic stem cells, the non-invasive and ethically favorable nature of placental stem cell collection contributes to their growing acceptance and utilization. Furthermore, increasing investments in biotechnology and healthcare sectors support the development and commercialization of placental stem cell therapies. Regulatory support and the establishment of robust clinical trial frameworks are also facilitating market expansion. The rising awareness about the benefits of stem cell therapies and their potential to treat a wide range of conditions, from blood disorders to tissue injuries, is driving demand. The increasing trend of personalized medicine, where treatments are customized to individual patient needs, further propels the placental stem cell therapy market. However, ethical concerns, regulatory hurdles, and the high costs associated with clinical trials and commercialization may hinder the growth of the placental stem cell therapy market in the next few years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Placental Stem Cell Therapy. The growth and trends of Placental Stem Cell Therapy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Placental Stem Cell Therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

• Hematologic Malignancies And Disorders
• Congenital Inmunodeficiency Disorders
• Metabolic Disorders
• Neurological Disorders

By End User

• Hospitals & Specialty Clinics
• Clinical Research Organizations
• Research Institutes & Academies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Placental Stem Cell Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Placental Stem Cell Therapy market include Lifebank Stem Cell Banking, Celularity Inc., Americord Registry, Reelabs Pvt. Ltd., Pluristem Therapeutics Inc., Mesoblast Limited, ReNeuron Group Plc, Athersys Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. PLACENTAL STEM CELL THERAPY - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Application
  • 3.7.2 Market Attractiveness Analysis By End User
  • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PLACENTAL STEM CELL THERAPY MARKET ANALYSIS BY APPLICATION

• 5.1. Overview By Application
• 5.2. Historical and Forecast Data Analysis By Application
• 5.3. Hematologic Malignancies And Disorders Historic and Forecast Sales By Regions
• 5.4. Congenital Inmunodeficiency Disorders Historic and Forecast Sales By Regions
• 5.5. Metabolic Disorders Historic and Forecast Sales By Regions
• 5.6. Neurological Disorders Historic and Forecast Sales By Regions

6. GLOBAL PLACENTAL STEM CELL THERAPY MARKET ANALYSIS BY END USER

• 6.1. Overview By End User
• 6.2. Historical and Forecast Data Analysis By End User
• 6.3. Hospitals & Specialty Clinics Historic and Forecast Sales By Regions
• 6.4. Clinical Research Organizations Historic and Forecast Sales By Regions
• 6.5. Research Institutes & Academies Historic and Forecast Sales By Regions

7. GLOBAL PLACENTAL STEM CELL THERAPY MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2 North America By Segment Sales Analysis
  • 7.3.3 North America By Country Sales Analysis
  • 7.3.4 United States Sales Analysis
  • 7.3.5 Canada Sales Analysis
  • 7.3.6 Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2 Europe By Segment Sales Analysis
  • 7.4.3 Europe By Country Sales Analysis
  • 7.4.4 United Kingdom Sales Analysis
  • 7.4.5 France Sales Analysis
  • 7.4.6 Germany Sales Analysis
  • 7.4.7 Italy Sales Analysis
  • 7.4.8 Russia Sales Analysis
  • 7.4.9 Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2 Asia Pacific By Segment Sales Analysis
  • 7.5.3 Asia Pacific By Country Sales Analysis
  • 7.5.4 China Sales Analysis
  • 7.5.5 India Sales Analysis
  • 7.5.6 Japan Sales Analysis
  • 7.5.7 South Korea Sales Analysis
  • 7.5.8 Australia Sales Analysis
  • 7.5.9 South East Asia Sales Analysis
  • 7.5.10 Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2 Latin America By Segment Sales Analysis
  • 7.6.3 Latin America By Country Sales Analysis
  • 7.6.4 Brazil Sales Analysis
  • 7.6.5 Argentina Sales Analysis
  • 7.6.6 Peru Sales Analysis
  • 7.6.7 Chile Sales Analysis
  • 7.6.8 Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2 Middle East & Africa By Segment Sales Analysis
  • 7.7.3 Middle East & Africa By Country Sales Analysis
  • 7.7.4 Saudi Arabia Sales Analysis
  • 7.7.5 UAE Sales Analysis
  • 7.7.6 Israel Sales Analysis
  • 7.7.7 South Africa Sales Analysis
  • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE PLACENTAL STEM CELL THERAPY COMPANIES

• 8.1. Placental Stem Cell Therapy Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9. COMPANY PROFILES OF PLACENTAL STEM CELL THERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Lifebank Stem Cell Banking
  • 9.3.1 Company Overview
  • 9.3.2 Company Revenue
  • 9.3.3 Products
  • 9.3.4 Recent Developments
• 9.4. Celularity Inc.
  • 9.4.1 Company Overview
  • 9.4.2 Company Revenue
  • 9.4.3 Products
  • 9.4.4 Recent Developments
• 9.5. Americord Registry
  • 9.5.1 Company Overview
  • 9.5.2 Company Revenue
  • 9.5.3 Products
  • 9.5.4 Recent Developments
• 9.6. Reelabs Pvt. Ltd.
  • 9.6.1 Company Overview
  • 9.6.2 Company Revenue
  • 9.6.3 Products
  • 9.6.4 Recent Developments
• 9.7. Pluristem Therapeutics Inc.
  • 9.7.1 Company Overview
  • 9.7.2 Company Revenue
  • 9.7.3 Products
  • 9.7.4 Recent Developments
• 9.8. Mesoblast Limited
  • 9.8.1 Company Overview
  • 9.8.2 Company Revenue
  • 9.8.3 Products
  • 9.8.4 Recent Developments
• 9.9. ReNeuron Group Plc
  • 9.9.1 Company Overview
  • 9.9.2 Company Revenue
  • 9.9.3 Products
  • 9.9.4 Recent Developments
• 9.10. Athersys Inc
  • 9.10.1 Company Overview
  • 9.10.2 Company Revenue
  • 9.10.3 Products
  • 9.10.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies